Advancement in the management of Von Hippel Landau (VHL) Disease: A Comprehensive Educational Program on hypoxia-inducible factor-2 alpha inhibitor (HIF-2a)

Advancement in the management of Von Hippel Landau (VHL) Disease: A Comprehensive Educational Program on hypoxia-inducible factor-2 alpha inhibitor (HIF-2a) is organized by Canadian Urological Association (CUA) / Association des urologues du Canada (AUC) and will be held on May 08, 2024.

Objectives:
By participating in this learning program, healthcare providers can expect to:
• Discuss the mechanism of action of HIF-2 inhibitors in suppressing tumor growth in VHL-related tumors.
• Examine the clinical efficacy and safety profile of HIF-2 inhibitors and impact on clinical practice.
• Explore strategies for early identification and management of side effects associated with HIF-2? inhibitors, based on evidence-based medicine and lessons learned from real-world experience.